Streamline Health Solutions (STRM) Q2 2025 earnings summary

Executive summary

• Q2 2024 revenue declined 22% year-over-year to $4.5 million, mainly due to client non-renewals, with SaaS revenue comprising up to 69% of total revenue and pro forma SaaS revenue growing 21% in the first six months of 2024, excluding a major client non-renewal.

• Net loss for Q2 2024 was $2.8 million ($0.05/share), compared to $2.5 million ($0.04/share) in Q2 2023; six-month net loss was $5.5 million versus $5.4 million year-over-year.

• Adjusted EBITDA loss improved to $0.3 million in Q2 2024 from $0.9 million in Q2 2023, reflecting cost savings from strategic restructuring.

• Strategic restructuring in late 2023 reduced expenses, with all related costs recognized by July 31, 2024.

• Management remains focused on expanding client footprint, product innovation, and achieving financial goals despite industry headwinds and client churn.

Financial highlights

• Total revenue for the six months ended July 31, 2024, was $8.8 million, down 21% year-over-year.

• SaaS revenue was $3.1 million (69% of total) in Q2 2024, up from 61% in Q2 2023; six months SaaS revenue was $5.8 million (66% of total).

• Adjusted EBITDA for Q2 2024 was $(0.3) million; six months: $(1.0) million, both improved year-over-year.

• Cash and cash equivalents as of July 31, 2024, were $3.5 million, up from $3.2 million at January 31, 2024.

• Total debt as of July 31, 2024, was $12.5 million.

Outlook and guidance

• Adjusted EBITDA breakeven run rate remains at $15.5 million implemented SaaS ARR, now targeted for the second half of fiscal 2025 due to client churn.

• Revenue is expected to remain relatively flat for the remainder of fiscal 2024, with growth anticipated in fiscal 2025 as new bookings are implemented.

• Management is focused on cost-saving initiatives and improving contract-to-implementation timelines.

• The company projects potential non-compliance with certain financial covenants in the next twelve months, raising substantial doubt about its ability to continue as a going concern.